Press releases
Access archived Guidant press releases
Access archived BTG press releases
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Feb 13, 2012
Boston Scientific Corporation (NYSE: BSX) announces that Moody's Investors Service has upgraded the Company's corporate credit rating to an investment...
-
Feb 8, 2012TruePath™ CTO Device designed to facilitate crossing of chronic total occlusions
Boston Scientific Corporation (NYSE: BSX) announces the U.S. launch of the TruePath™ CTO Device, designed to facilitate the crossing of chronic total...
-
Feb 7, 2012
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Leerink Swann 2012 Global Healthcare Conference on February 15 in New York....
-
Feb 7, 2012Studies published in peer-reviewed medical journals
Boston Scientific Corporation (NYSE: BSX) welcomes positive results from three studies of the WallFlex® Enteral Stent Systems, a family of...
-
Feb 6, 2012Boston Scientific Announces Global Launch of Expect™ 19 Flex Endoscopic Ultrasound Aspiration NeedleNew device offers excellent flexibility and large size for acquiring tissue samples
Boston Scientific Corporation (NYSE: BSX) announces the global launch of the Expect 19 Flex Endoscopic Ultrasound Aspiration Needle, used for acquiring...
-
Feb 3, 2012
Paris, France and Miami Beach, FL (February 3, 2012) – Boston Scientific Corporation (NYSE: BSX) announces CE Mark approval of the Infinion™ 16 Percutaneous Lead for its Precision Plus™...
-
Feb 2, 2012
Boston Scientific Corporation (NYSE: BSX) announces financial results for the fourth quarter and full year ended December 31, 2011, as well as sales and...
-
Feb 1, 2012Platinum chromium coronary stent with enhanced delivery system now available in Europe and other international countries
Boston Scientific Corporation (NYSE: BSX) announces first patient use and European market launch of the PROMUS Element™ Plus Everolimus-Eluting...
-
Jan 31, 2012
Singapore (January 31, 2012) – Boston Scientific Corporation (NYSE: BSX) announces the creation of its Asia-Pacific regional organization that includes Australia, New Zealand, China, Hong Kong,...
-
Jan 26, 2012NICE Report Supports Safety and Effectiveness of Alair® System
London (January 26, 2012) -- Boston Scientific (UK) welcomes new guidance from the National Institute for Health and Clinical Excellence (NICE) on the use of Bronchial Thermoplasty (BT) to treat...
-
Jan 23, 2012Johnson and Johnson's patents found invalid
Boston Scientific Corporation (NYSE: BSX) announces that the U.S. District Court for the District of New Jersey has found all the asserted patents in...
-
Jan 20, 2012
Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the fourth quarter and full year ended...
-
Jan 16, 2012Nine-month data presented at ISET support safety and efficacy of Epic Stent in iliac stenting
Boston Scientific Corporation (NYSE: BSX) reports nine-month clinical endpoint data from its ORION trial, demonstrating excellent outcomes...
-
Jan 4, 2012Boston Scientific's Alair® Bronchial Thermoplasty System Achieves Important Reimbursement MilestonesCMS pass-through payment and new CPT®[1] codes established for catheter-based procedure to treat severe asthma
Boston Scientific Corporation (NYSE: BSX) announced that the Centers for Medicare and Medicaid Services (CMS), the agency that administers the Medicare...
-
Jan 3, 2012
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 30th Annual J.P. Morgan Healthcare Conference in San Francisco. Hank...
-
Dec 12, 2011
Boston Scientific Corporation (NYSE: BSX) announces the U.S. launch of its Charger™ PTA Balloon Catheter, a 0.035" percutaneous transluminal...
-
Dec 8, 2011World's first and only 16-contact percutaneous lead provides innovative, new option for physicians to treat chronic pain
Boston Scientific Corporation (NYSE: BSX) announces U.S. Food and Drug Administration (FDA) approval of the Infinion™ 16 Percutaneous...
-
Nov 30, 2011Extended ICD/CRT-D program offers warranties up to 10 years
Boston Scientific Corporation (NYSE: BSX) announced that, along with today's introduction of a new family of INCEPTA™ and ENERGEN™ implantable...
-
Nov 30, 2011New family of cardiac devices offers excellent longevity and industry's longest warranty
Boston Scientific Corporation (NYSE: BSX) announces FDA approval of its INCEPTA™, ENERGEN™ and PUNCTUA™ cardiac resynchronization therapy...
-
Nov 22, 2011Approval marks transition to internally manufactured everolimus-eluting stent in the U.S.
Boston Scientific Corporation (NYSE: BSX) announces U.S. Food and Drug Administration (FDA) approval for the PROMUS Element™ Plus Everolimus-Eluting...
-
Nov 18, 2011
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Piper Jaffray 23rd Annual Healthcare Conference on November 30 in New...
-
Nov 16, 2011Innovative left atrial appendage closure device offers proven alternative to anticoagulant drugs for patients in atrial fibrillation at high risk for stroke
Boston Scientific Corporation's (NYSE: BSX) WATCHMAN® Left Atrial Appendage (LAA) Closure Device has been implanted in the first patients in Latin...
-
Nov 15, 2011
Boston Scientific Corporation (NYSE: BSX) commends the leadership of Senator Al Franken (D-MN), Senator Lamar Alexander (R-TN) and Senator John Kerry...
-
Nov 11, 2011Positive results from COBRA trial presented at TCT
Boston Scientific Corporation (NYSE: BSX) welcomed positive outcomes from the COBRA clinical trial, which evaluated post-dilation of...
-
Nov 11, 2011EVOLVE trial evaluates fourth-generation everolimus-eluting coronary stent with ultra-thin abluminal bioabsorbable polymer
Boston Scientific Corporation (NYSE: BSX) reports results from the EVOLVE First Human Use trial demonstrating the non-inferiority of...
-
Nov 8, 2011
Boston Scientific Corporation (NYSE: BSX) reports positive outcomes from the CABANA post-approval study of the Carotid WALLSTENT®...
-
Nov 8, 2011PLATINUM Long Lesion clinical results presented at TCT show no cardiac death, heart attack or stent thrombosis at one year
Boston Scientific Corporation (NYSE: BSX) reports clinical endpoint data from its PLATINUM Long Lesion trial, demonstrating excellent...
-
Nov 8, 2011Long-term results presented from two studies evaluating advanced paclitaxel-eluting stent
Boston Scientific Corporation (NYSE: BSX) reports positive long-term data from the PERSEUS clinical program, which demonstrated...
-
Nov 2, 2011Multi-center study published in Gastrointestinal Endoscopy is largest ever reported on peroral cholangioscopy
Boston Scientific Corporation (NYSE: BSX) welcomes study results published in the October issue of Gastrointestinal Endoscopy showing an overall...
-
Nov 1, 2011Clinical presentations to include 12-month data on fourth-generation SYNERGY™ Stent
Boston Scientific Corporation (NYSE: BSX) releases the schedule of its major events and product-related clinical research for the Cardiovascular...
-
Oct 27, 2011Video demonstration of CardioTeach™ app by Dr. Kenneth Stein available online
Boston Scientific Corporation (NYSE: BSX) introduces its CardioTeach™ iPad® app, an industry-first, free educational resource to help healthcare...
-
Oct 20, 2011
Boston Scientific Corporation (NYSE: BSX) announces financial results for the third quarter ended September 30, 2011, as well as updated sales and...
-
Oct 18, 2011
Boston Scientific Corporation (NYSE: BSX) has completed enrollment in a clinical trial to evaluate its WallFlex® Biliary RX Fully Covered Stent for...
-
Oct 17, 2011Company's everolimus-eluting platinum chromium stent now being marketed in world's second-largest DES market
Boston Scientific Corporation (NYSE: BSX) has begun a phased launch of its PROMUS Element™ Everolimus-Eluting Platinum Chromium Coronary Stent System...
-
Oct 14, 2011
Boston Scientific Corporation (NYSE: BSX) welcomes yesterday's introduction of the Medical Device Regulatory Improvement Act, sponsored by Sen. Amy...
-
Oct 11, 2011
Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the third quarter ended September 30, 2011...
-
Oct 5, 2011Third-generation bare-metal stent designed to offer improved acute performance in treating patients with coronary artery disease
Boston Scientific Corporation (NYSE: BSX) has started patient enrollment in the OMEGA clinical trial, designed to evaluate the safety and effectiveness...
-
Sep 29, 2011Study designed to assess preliminary safety and efficacy of chronic vagal nerve stimulation in heart failure patients
Boston Scientific Corporation (NYSE: BSX) has enrolled the first patients in its NECTAR-HF (NEural Cardiac TherApy foR Heart Failure) clinical trial....
-
Sep 28, 2011
Boston Scientific Corporation (NYSE: BSX) today announced that the U.S. Court of Appeals for the Federal Circuit found in favor of the Company in a...
-
Sep 19, 2011Ultra-low profile, highly deliverable balloon dilatation catheter offers physicians exceptional performance in peripheral angioplasty procedures
Boston Scientific Corporation (NYSE: BSX) has launched its Coyote™ Balloon Catheter, a highly deliverable and ultra-low profile 0.014 inch balloon...
-
Sep 15, 2011Company supports women's health through online community launched by American Urogynecologic Society (AUGS) at annual meeting
Boston Scientific Corporation (NYSE: BSX) is further supporting the advancement of women's health as the founding sponsor of the American...
-
Sep 13, 2011Mahoney Has Served as Worldwide Chairman, Medical Device and Diagnostics Group, Johnson & Johnson
Attracting one of med-tech's most inspiring leaders, Boston Scientific Corporation (NYSE: BSX) has named Michael Mahoney, 46, as President of the...
-
Sep 9, 2011
Boston Scientific Corporation (NYSE: BSX) today issued the following statement from John Pedersen, Senior Vice President and President of the Company's...
-
Sep 2, 2011
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Morgan Stanley Global Healthcare Conference on September 14 in New York....
-
Sep 2, 2011
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Morgan Stanley Global Healthcare Conference on September 14 in New York....
-
Aug 10, 2011Company also introduces industry's first iPhone®/iPad® app for healthcare professionals using SCS
Boston Scientific Corporation (NYSE: BSX) has launched its Neuromodulation Learning Institute™ (NLI), a clinical education program and online...
-
Aug 9, 2011Company's fully covered metal stent now approved in Canada for use in treating benign biliary strictures
Natick, MA (August 9, 2011) – Boston Scientific Corporation’s (NYSE: BSX) WallFlex® Biliary RX Fully Covered Stent has received Health Canada approval for the treatment of benign biliary...
-
Aug 8, 2011
Boston Scientific Corporation (NYSE: BSX) today announces the U.S. Court of Appeals for the First Circuit has affirmed the dismissal of a...
-
Aug 8, 2011Investment supported by grant funding from Government through IDA Ireland
Clonmel, 8th August 2011 – Boston Scientific Corporation (NYSE: BSX) and Irish Minister for Jobs, Enterprise and Innovation, Richard Bruton TD, announced that the Company is investing €26...
-
Jul 28, 2011Company also announces new share repurchase, China investment and restructuring program
Boston Scientific Corporation (NYSE: BSX) today announces financial results for the second quarter ended June 30, 2011, as well as net sales and...